Based on the evidence, I predict that CAR T cells manufactured with or engineered to express interleukin-15 will exhibit a more potent pro-inflammatory cytokine release (including IFN-γ, TNF-α, and IL-2) upon antigen stimulation compared to CAR T cells manufactured without interleukin-15.